Rapha Capital PE Life Sciences Fund VI, LP
Raised
$1M
Investors
2
Min Invest
$250,000
AltStreet Analysis
·Generated from EDGAR primary sources
Rapha Capital PE Life Sciences Fund VI, LP is a Delaware limited partnership that filed an original Form D on 2023-02-08 under Rule 506(b). The fund raised $1.1M from 2 investors with a $250K minimum investment. Related persons include Kevin Slawin (Executive Officer, Promoter), Rapha Capital PE Life Sciences Fund GP, LLC (Promoter), and Rapha Capital Management, LLC (Promoter).
This is a private equity life sciences fund operating under the standard 506(b) exemption, which permits general solicitation restrictions. The $250K minimum investment positions it in the lower tier for institutional alternative investments, though the early-stage capital raise of $1.1M suggests an initial close or emerging fund launch.
Data Flags
EDGAR Filing Data
Form D — Primary Source
View on SEC.govFilings on Record
Every filing AltStreet's ledger holds for this CIK, newest first. Each opens the SEC archive folder.
In the Terminal
Filing events
0
none on file
Critical / warning
0 / 0
0 watch · 0 info
Statements extracted
0
none on file
NAV prints
0
none on file
Offering chains
1
lapsed
Investor
- 1 offering timeline: velocity, share raised, first-sale lag, stalled flags
Pro
- This issuer against its cohort: rank by velocity and share raised among offerings filed the same quarter
- The same events, statements and NAV moves across every issuer, screenable, with unlimited watches and CSV
Counts and dates above are the free record. The values, the series and the comparisons are the seat. Loading your view…
Related Persons (Form D)
Executive officers, directors, and promoters listed on the SEC Form D filing. Source: SEC.gov.
Kevin Slawin
Executive Officer, Promoter · Surfside, FL
n/a Rapha Capital PE Life Sciences Fund GP, LLC
Promoter · Surfside, FL
n/a Rapha Capital Management, LLC
Promoter · Surfside, FL
Questions About Rapha Capital PE Life Sciences Fund VI, LP
Each answer is built from the values on the SEC filing and the AltStreet ledger, not from the issuer's marketing.
What is Rapha Capital PE Life Sciences Fund VI, LP?
Rapha Capital PE Life Sciences Fund VI, LP is a Delaware limited partnership that filed a Form D with the SEC on February 8, 2023 as a venture capital fund. The filing claims Rule 506(b) for an offering of equity.
Is Rapha Capital PE Life Sciences Fund VI, LP legit?
AltStreet does not rate legitimacy; it reports the public record. Rapha Capital PE Life Sciences Fund VI, LP filed a Form D with the SEC on February 8, 2023 claiming Rule 506(b). A Form D is a notice of an exempt offering, not a review or approval of it. The newest notice reports $1,100,000 sold to 2 investors. AltStreet's enforcement record (SEC, FINRA and state actions) shows no action naming the issuer as of today. Before investing, confirm the filing on EDGAR, check the seller's registration on FINRA BrokerCheck, and read the offering documents, which a Form D does not include.
Is Rapha Capital PE Life Sciences Fund VI, LP registered with or approved by the SEC?
No. A Form D is a notice that an issuer is selling securities under an exemption from registration, and the SEC does not review, approve, or pass on the merits of the offering. The filing shows that Rapha Capital PE Life Sciences Fund VI, LP claimed Rule 506(b) and disclosed the items the form requires, such as the amount sold, the minimum investment, related persons, and anyone paid to sell the securities. It does not verify the issuer's claims or its business.
How much has Rapha Capital PE Life Sciences Fund VI, LP raised?
Rapha Capital PE Life Sciences Fund VI, LP reported $1,100,000 sold from 2 investors in an offering of indefinite size as of the Form D filed February 8, 2023.
Who can invest in Rapha Capital PE Life Sciences Fund VI, LP?
The offering relies on Rule 506(b), which permits sales to accredited investors and to no more than 35 non-accredited investors who meet a sophistication standard, and prohibits general solicitation. The filing reports no non-accredited investors. The minimum investment accepted from an outside investor is $250,000.
What is the minimum investment in Rapha Capital PE Life Sciences Fund VI, LP?
The Form D lists $250,000 as the minimum investment accepted from any outside investor as of February 8, 2023. Issuers can waive their own minimums, and the figure does not include fees.
Who is selling Rapha Capital PE Life Sciences Fund VI, LP and how are they paid?
The Form D names no recipient of sales compensation, which usually means the issuer or its affiliates are placing the securities directly.
Who is behind Rapha Capital PE Life Sciences Fund VI, LP?
The Form D lists 3 related persons: Kevin Slawin, executive officer, promoter (Manager of the Investment Manager of the Issuer); Rapha Capital PE Life Sciences Fund GP, LLC, promoter (General Partner of the Issuer); Rapha Capital Management, LLC, promoter (Investment Manager of the Issuer). Form D Item 3 requires executive officers, directors, and promoters of the issuer to be listed.
Where is Rapha Capital PE Life Sciences Fund VI, LP located?
The issuer's address on its SEC filings is 9511 Collins Ave., #1403, Surfside, FL 33154. Its phone number of record is (305) 809-6920. It is organized under the laws of Delaware.
How long is the Rapha Capital PE Life Sciences Fund VI, LP offering open?
The issuer indicated that the offering is not intended to last more than one year. An issuer must amend its Form D annually while a continuing offering stays open, and no amendment is on record yet.
How large is Rapha Capital PE Life Sciences Fund VI, LP?
The issuer declined to disclose its revenue range on the Form D, which the form permits.
Is this your offering?
Claim this profile to add contact information, team members, LinkedIn profiles, fund history, and additional financial data. EDGAR-sourced data and AltStreet analysis cannot be edited, but corrections can be requested for verifiable inaccuracies.
Data Methodology
Capital raise figures, investor counts, and filing dates are sourced directly from SEC EDGAR Form D primary documents via the SEC EDGAR submissions API and full-text search index. EDGAR entity profiles and deal-level data are reviewed by AltStreet analysts with backgrounds in corporate finance and securities law — cross-referenced against offering circulars, audited financial statements, and primary regulatory filings before publication. Platform-provided information, where present, is clearly labeled and does not affect EDGAR data or AltStreet editorial coverage. Platforms may request factual corrections for demonstrable inaccuracies by contacting [email protected]. This page does not constitute investment advice.